Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C32H43NO4
CAS Number:
Molecular Weight:
505.69
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352205
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
application(s)
metabolomics
vitamins, nutraceuticals, and natural products
storage temp.
−20°C
SMILES string
CC1(C)CC[C@]2(C(OC)=O)CC[C@@]([C@@]3([H])[C@]2([H])C1)(C)[C@]4(C)CC[C@@]5([H])C(C)(C)C(C(C#N)=C[C@]5(C)C4=CC3=O)=O
InChI
1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
InChI key
WPTTVJLTNAWYAO-KPOXMGGZSA-N
Gene Information
human ... IKBKB(3551), KEAP1(9817), NFE2L2(4780), PPARG(5468)
General description
CDDO-Me is a synthetic triterpenoid compound with anti-inflammatory, anti-tumor and cytoprotective properties. It is derived from the natural product oleanic acid.
Application
CDDO Methyl Ester has been used to test its effect on hepatocyte membrane transporters (HMTs) regulation and mitigation of cholestasis in hepatic ischemia-reperfusion injury (IRI). It has also been used activator of NF E2 Related Factor 2 (NRF2) to study its role in preventing cell death in melanoma cells.
Biochem/physiol Actions
CDDO-Me inhibits inflammatory mediators including interleukin-6 (IL-6), IL-10, and IL-12. It enhances apoptosis induced by TNF and chemotherapeutic agents. CDDO-Me exhibits anti-proliferative activity in osteosarcoma cells and enhances the effectiveness of chemotherapeutic agents by inducing an intrinsic mitochondrial-dependent apoptotic pathway. It can be used as an adjuvant treatment for advanced and fatal form of prostate cancer.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Pharmacological STING Activation Is a Potential Alternative to Overcome Drug-Resistance in Melanoma.
Sandhya Chipurupalli et al.
Frontiers in oncology, 10, 758-758 (2020-06-02)
Melanoma is the most aggressive type of skin cancer and resistance to the conventional chemotherapy is the major cause for its poor prognosis. Metabolic perturbations leading to increased production of reactive oxygen species activate NRF2-dependent anti-oxidative responses to survive oxidative
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection
Tran T A, et al.
Journal of Neuroinflammation, 5(1), 1-1 (2008)
Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes.
Eitas T K, et al.
PLoS ONE, 12(9), e0184164-e0184164 (2017)